Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
Spero Therapeutics Inc (NASDAQ: SPRO) closed the day trading at $2.64 down -6.05% from the previous closing price of $2.81. In other words, the price has decreased by -$6.05 from its previous closing price. On the day, 0.91 million shares were traded. SPRO stock price reached its highest trading level at $2.835 during the session, while it also had its lowest trading level at $2.6148.
Ratios:
For a better understanding of SPRO, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.56 and its Current Ratio is at 2.56. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.06.
On September 23, 2022, Evercore ISI Upgraded its rating to Outperform which previously was In-line and also upped its target price recommendation from $2 to $8.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 05 ’25 when Keutzer Timothy sold 56,537 shares for $0.78 per share. The transaction valued at 44,099 led to the insider holds 741,439 shares of the business.
Rajavelu Esther sold 20,689 shares of SPRO for $16,137 on Feb 05 ’25. The CFO & CBO now owns 724,720 shares after completing the transaction at $0.78 per share. On Feb 05 ’25, another insider, Shukla Sath, who serves as the CEO & President of the company, sold 155,333 shares for $0.78 each. As a result, the insider received 121,160 and left with 1,736,883 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SPRO now has a Market Capitalization of 147603984 and an Enterprise Value of 117213856. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.22 while its Price-to-Book (P/B) ratio in mrq is 4.36. Its current Enterprise Value per Revenue stands at 2.629 whereas that against EBITDA is -1.602.
Stock Price History:
The Beta on a monthly basis for SPRO is 1.41, which has changed by 0.76 over the last 52 weeks, in comparison to a change of 0.10611236 over the same period for the S&P500. Over the past 52 weeks, SPRO has reached a high of $3.22, while it has fallen to a 52-week low of $0.51. The 50-Day Moving Average of the stock is 30.80%, while the 200-Day Moving Average is calculated to be 112.65%.
Shares Statistics:
Over the past 3-months, SPRO traded about 4.40M shares per day on average, while over the past 10 days, SPRO traded about 1024800 shares per day. A total of 55.90M shares are outstanding, with a floating share count of 37.21M. Insiders hold about 33.45% of the company’s shares, while institutions hold 20.67% stake in the company. Shares short for SPRO as of 1749772800 were 1612678 with a Short Ratio of 0.39, compared to 1747267200 on 636730. Therefore, it implies a Short% of Shares Outstanding of 1612678 and a Short% of Float of 3.52.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current assessment of Spero Therapeutics Inc (SPRO) involves the perspectives of 1.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.25, with high estimates of -$0.25 and low estimates of -$0.25.
Analysts are recommending an EPS of between -$0.84 and -$0.84 for the fiscal current year, implying an average EPS of -$0.84.
Revenue Estimates
A total of 1 analysts have provided revenue estimates for SPRO’s current fiscal year. The highest revenue estimate was $5.9M, while the lowest revenue estimate was $5.9M, resulting in an average revenue estimate of $5.9M. In the same quarter a year ago, actual revenue was $47.98MBased on 1 analysts’ estimates, the company’s revenue will be $1.3M in the next fiscal year. The high estimate is $1.3M and the low estimate is $1.3M.
